Pantheon Vision, a Baltimore, MD-based early-stage ophthalmic medical device company, raised $2.5M in Seed funding.
The round saw participation from KeraLink International (KLI), a forward-thinking and innovative non-profit, 501(c)(3) organization driven by empathy and compassion.
The company intends to use the funds to expand its R&D sector, operations and its business reach.
Led by John Sheets, Ph.D., CEO, Pantheon Vision is committed to developing advanced bioengineered solutions that can treat corneal blindness and restore vision for people around the world. The company is creating bioengineered implants to raise the standard of eye care globally and reduce reliance on donated corneal tissue, which is often unavailable in low- and middle-income countries (LMICs). The company will engage the U.S. Food and Drug Administration (FDA) in the coming months to guide plans for global product development.
Dr. Sheets has led companies including Hoya and Elisar, and R&D organizations at Alcon, Bausch & Lomb, and Johnson & Johnson. He also headed the Office of Device Evaluation at the FDA. The company is comprised of additional ophthalmic industry executives and supported by a world-class Scientific Advisory Board.
FinSMEs
03/11/2023